7549Background: Bruton tyrosine kinase (BTK) inhibition has shown clinical benefit in FL. Acalabrutinib is a highly selective, potent, covalent inhibitor of BTK. We evaluated acalabrutinib ± R in a Phase 1b study of patients (pts) with treatment-naive (TN) or relapsed/refractory (R/R) FL. Methods: Pts with R/R FL (≥1 prior treatment) were randomized to acalabrutinib (mono) or acalabrutinib + R (combo); TN pts received the combo. In 28-day cycles, R (375 mg/m2 IV) was given weekly in Cycle 1 and on Day 1 of Cycles 2-6; acalabrutinib (100 mg PO bid [2 pts received 200 mg qd]) was given until progressive disease (PD) or intolerance. The primary endpoint was safety. Secondary endpoints included overall response rate (ORR), duration of response (DOR), pharmacokinetics (PK) and pharmacodynamics. Results: Thirteen TN and 27 R/R pts were treated. In all pts, the median age was 66 years (range 32-83), 98% of pts had ECOG PS ≤1, and 88% had stage III/IV disease. R/R pts received a median of 2 prior therapies (range...